Key result
PCSK9 variants associate more weakly with ischemic stroke than with CHD, contrasting pharmacological inhibition.
Why the study?
Do PCSK9 genetic variants have different effects on the risk of ischaemic stroke compared to coronary heart disease?
Do PCSK9 genetic variants have different effects on the risk of ischaemic stroke compared to coronary heart disease?
No takes yet. Share an insight, caveat, or question.
The discrepancy between Mendelian randomization and randomized trial results for PCSK9 inhibition on stroke risk highlights limitations in using genetic variants to predict therapeutic effects.
Hopewell et al. (2017) conducted a review in Coronary heart disease and ischaemic stroke. PCSK9 genetic variants was evaluated on Risk of ischaemic stroke (IS) and coronary heart disease (CHD). PCSK9 genetic variants conferring lower LDL-C levels have weaker associations with ischemic stroke risk than coronary heart disease risk, contrasting with therapeutic PCSK9 inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: